Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

Journal of Neuro-Oncology

Volumn 96, Issue 3, 2010, Pages 393-402

  Dresemann, Gregor ^a   Weller, Michael ^b   Rosenthal, Mark A ^c   Wedding, Ulrich ^d   Wagner, Wolfgang ^e   Engel, Erik ^e   Heinrich, Bernhard ^f   Mayer Steinacker, Regine ^g   Karup Hansen, Anders ^h   Fluge, Eystein ⁱ   Nowak, Anna ^j   Mehdorn, Maximilian ^k   Schleyer, Eberhard ^l   Krex, Dietmar ^m   Olver, Ian N ⁿ   Steinbach, Joachim P ^b   Hosius, Christian ^o   Sieder, Christian ^o   Sorenson, Greg ^p   Parker, Richard ^q   Nikolova, Zariana ^q   more..

^a Zentrum für Neuro Onkologie Am Ärztehaus Velen   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e Hämatologisch Onkologische Praxis ^*  (Germany)

^f Hamatologisch Onkologische Praxis   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l Karl von Basedow Klinikum   (Germany)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ Cancer Council Australia   (Australia)

^o Novartis Pharma AG   (Germany)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

^q NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

GBM; Glioblastoma; Hydroxyurea; Imatinib; Recurrent

Indexed keywords

HYDROXYUREA; IMATINIB; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APHASIA; ARTICLE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; GENERAL CONDITION DETERIORATION; GLIOBLASTOMA; HAZARD RATIO; HEMIPARESIS; HUMAN; INTRACRANIAL PRESSURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75049085049     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9976-3     Document Type: Article

References (17)

1. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
2. S Sathornsumetee DA Reardon A Desjardins, et al. 2007 Molecularly targeted therapy for malignant glioma Cancer 110 13 24 10.1002/cncr.22741 10.1002/cncr.22741 17520692 (Pubitemid 46986413)
3. H Joensuu M Puputti H Sihto, et al. 2005 Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme J Pathol 207 224 231 10.1002/path.1823 10.1002/path.1823 1:CAS:528:DC%2BD2MXhtFKnsr%2FO 16021678 (Pubitemid 41404153)
4. LW Buie JM Valgus 2008 Bevacizumab: a treatment option for recurrent glioblastoma multiforme Ann Pharmacother 42 1486 1490 10.1345/aph.1L030 10.1345/aph.1L030 1:CAS:528:DC%2BD1cXht1enurrO 18765835
5. E Raymond A Brandes A Van Oosterom, et al. 2004 Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC:NDDG/BTG intergroup study Proc Am Soc Clin Oncol 23 107 abstract
6. PY Wen WK Yung KR Lamborn, et al. 2006 Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumour Consortium Study 99-08 Clin Cancer Res 12 4899 4907 10.1158/1078-0432.CCR-06-0773 1:CAS:528:DC%2BD28XotFKgt70%3D 16914578 (Pubitemid 44338577)
7. GW Canute SL Longo JA Longo, et al. 1998 The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme Neurosurgery 42 609 616 10.1097/00006123-199803000-00031 10.1097/00006123- 199803000-00031 1:STN:280:DyaK1c7os1Wqsw%3D%3D 9526995 (Pubitemid 28128745)
8. PY Wen S Kesari 2008 Malignant gliomas in adults N Engl J Med 359 492 507 10.1056/NEJMra0708126 10.1056/NEJMra0708126 1:CAS:528:DC%2BD1cXpt1Sgsrw%3D 18669428
9. G Dresemann 2003 STI 571/hydroxyurea in progressive, pretreated glioblastoma (GB) patients (pts.) Proc Am Soc Clin Oncol 22 116 ASCO abstract 465
10. G Dresemann 2004 Imatinib (STI571) plus hydroxyurea: safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts) Proc Am Soc Clin Oncol 23 119 abstract
11. G Dresemann 2005 Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series Ann Oncol 16 1702 1708 10.1093/annonc/mdi317 10.1093/annonc/mdi317 1:STN:280:DC%2BD2MvpvFKiug%3D%3D 16033874 (Pubitemid 41510147)
12. Reardon DA, Friedman AH, Herndon JE et al (2004) Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma [Abstract T-47]. In: Society for neuro-oncology 9th annual meeting, Toronto
13. DA Reardon MJ Egorin JA Quinn, et al. 2005 Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme J Clin Oncol 23 9359 9368 10.1200/JCO.2005.03.2185 10.1200/JCO.2005.03.2185 1:CAS:528:DC%2BD28Xnt1ymsw%3D%3D 16361636 (Pubitemid 46260195)
14. UM Schrell MG Rittig M Anders, et al. 1997 Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea J Neurosurg 86 840 844 10.3171/jns.1997.86. 5.0840 1:CAS:528:DyaK2sXms12ht70%3D 9126900
15. DR Macdonald TL Cascino SC Schold Jr, et al. 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
16. E Raymond AA Brandes C Dittrich, et al. 2008 Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 4659 4665 10.1200/JCO.2008.16.9235 10.1200/JCO.2008.16.9235 1:CAS:528:DC%2BD1cXht1KqtLfL 18824712
17. S Pursche E Schleyer M von Bonin, et al. 2008 Influence of enzyme-inducing antiepileptic drugs on trough level on imatinib in glioblastoma patients Curr Clin Pharmacol 3 198 203 10.2174/157488408785747656 10.2174/157488408785747656 1:CAS:528:DC%2BD1MXitF2hsbc%3D 18781906